Cognition Therapeutics published the results of the Phase 2 SEQUEL study on July 21, 2025, showing that the drug zervimesine protects neurons and synapses in the context of Alzheimer's disease.
4 reports, 1 independent
Updated Jul 21
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cognition Therapeutics published the results of the Phase 2 SEQUEL study on July 21, 2025, showing that the drug zervimesine protects neurons and synapses in the context of Alzheimer's disease.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Cognition Therapeutics publishes Phase 2 results for zervimesine in SEQUEL study for Alzheimer's disease.1 source
FDA reviewed Phase 2 results for Zervimesine, a drug from Cognition Therapeutics.1 source
Keep exploring
The entities involved
-
Cognition Therapeutics (United States)
company in Pittsburgh, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireCognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease In Vitro Experiments Showing Protection of Neurons under Diseas
- GlobeNewswireCognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC - Zervimesine-treated part
- GlobeNewswireCognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease Positive Discussion on Path Forward for Registrational Program PURCHASE, N.Y., July 10
- Unknown outlet